Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea

Acta Neurologica Taiwanica

Volumn 15, Issue 3, 2006, Pages 170-176

  Su, Cheng San ^a   Lan, Min Yu ^a   Liu, Jia Shou ^a   Chang, Chiung Chih ^a   Lai, Shung Lon ^a   Wu, Hsiu Shan ^a   Chen, Shun Sheng ^a   Chang, Yung Yee ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Botulinum toxin; Drooling; Parkinsonism; Salivary glands; Sialorrhea

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DYSPHAGIA; FEMALE; HUMAN; HYPERSALIVATION; MALE; PARKINSONISM; PAROTID GLAND; SHY DRAGER SYNDROME; SUBMANDIBULAR GLAND; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; INJECTIONS; MALE; PARKINSONIAN DISORDERS; SIALORRHEA;

EID: 33748769815     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726-32.
2. Eadie MJ, Tyrer JH. Alimentary Disorder in Parkinsonism. Australas Ann Med 1965;14:13-22.
3. Bateson MC, Gibberd FB, Wilson RS. Salivary symptoms in Parkinson disease. Arch Neurol 1973;29:274-5.
4. Proulx M, de Courval FP, Wiseman MA, et al. Salivary production in Parkinson's disease. Mov Disord 2005;20:204-7.
5. Hockstein NG, Samadi DS, Gendron K, et al. Sialorrhea: a management challenge. Am Fam Physician 2004;69:2628-34.
6. Tscheng DZ. Sialorrhea - therapeutic drug options. Ann Pharmacother 2002;36:1785-90.
7. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci 2005;235:1-9.
8. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord 2004;19(Suppl 8):S137-41.
9. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses 1997;48:337-9.
10. Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999;67:697.
11. Jost WH. Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999;14:1057.
12. Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-3.
13. O'Sullivan JD, Bhatia KP, Lees AJ. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;55:606-7.
14. Pal PK, Calne DB, Calne S, et al. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7.
15. Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7:329-32.
16. Porta M, Gamba M, Bertacchi G, et al. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001;70:538-40.
17. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81.
18. Ellies M, Laskawi R, Rohrbach-Volland S, et al. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003;61:454-7.
19. Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003;18:685-8.
20. Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004;114:620-7.
21. Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6.
22. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
23. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
24. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-8.
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
26. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park: Macmillan Health Care Information, 1987:153-63.
27. Crysdale WS, White A. Submandibular duct relocation for drooling: a 10-year experience with 194 patients. Otolaryngol Head Neck Surg 1989;101:87-92.
28. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46.
29. Tintner R, Gross R, Winzer UF, et al. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005;65:765-7.
30. Shaari CM, Wu BL, Biller HF, et al. Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol Head Neck Surg 1998;118:452-7.
31. Ellies M, Laskawi R, Gotz W, et al. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 1999;256:148-52.
32. Naumann M, Flachenecker P, Brocker EB, et al. Botulinum toxin for palmar hyperhidrosis. Lancet 1997;349:252.
33. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;323:596-9.
34. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;344:488-93.
35. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol 1995;115:459-61.
36. Naumann M, Zellner M, Toyka KV, et al. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997;42:973-5.
37. Boroojerdi B, Ferbert A, Schwarz M, et al. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 1998;65:111-4.
38. Riemann R, Pfennigsdorf S, Riemann E, et al. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology 1999;106:2322-4.
39. Kim KS, Kim SS, Yoon JH, et al. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 1998;112:248-51.
40. Unal M, Sevim S, Dogu O, et al. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol (Stockh) 2003;123:1060-3.
41. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-80.
42. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002;249:57-63.
43. Koman LA, Mooney JF 3rd, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20:108-15.
44. Winterholler MG, Erbguth FJ, Wolf S, et al. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001;70:417-8.
45. Tan EK, Lo YL, Seah A, et al. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001;190:95-7.